Experimental leukemia drug trial halted early

NCT ID NCT05168202

Terminated Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called CC-95251, alone or with other cancer drugs, in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that had come back or not responded to treatment. The main goals were to check safety and find the right dose. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Local Institution - 0001

Houston, Texas, 77030, United States
Local Institution - 0005

Heidelberg, Victoria, 3084, Australia
Local Institution - 0006

Clayton, Victoria, 3168, Australia
Local Institution - 0010

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 0011

Vancouver, British Columbia, V5Z 1M9, Canada
Local Institution - 0013

Oslo, N-0027, Norway
Local Institution - 0014

Stockholm, 141 86, Sweden
Local Institution - 0015

Lund, 22185, Sweden
Local Institution - 0017

Rozzano, 20089, Italy
Local Institution - 0018

Meldola, Emilia-Romagna, 47014, Italy
Local Institution - 0019

Edmonton, Alberta, T6G 2B7, Canada
Local Institution - 0020

Pessac, 33600, France
Local Institution - 0021

Gothenburg, 413 45, Sweden
Local Institution - 0023

Toulouse, 31059, France
Local Institution - 0025

Bergen, 5021, Norway
Local Institution - 0026

Milan, 20162, Italy
Local Institution - 0027

Wollongong, New South Wales, 2500, Australia
Local Institution - 0028

Santander, 39008, Spain
Local Institution - 0029

Nantes, 44000, France
Local Institution - 0030

Los Angeles, California, 90095, United States
Local Institution - 0031

Palo Alto, California, 94304, United States
Local Institution - 0032

Badalona, Barcelona [Barcelona], 08916, Spain
Local Institution - 0035

Salamanca, 37007, Spain
Local Institution - 0036

Madrid, 28007, Spain
Local Institution - 0037

Melbourne, Victoria, 3065, Australia
Local Institution - 0038

Montreal, Quebec, H3T 1E2, Canada
Local Institution - 0039

Barcelona, 08041, Spain
Local Institution - 0040

Marseille, 13009, France
Local Institution - 0041

Villejuif, 94805, France
Local Institution - 0044

Edinburgh, Midlothian, EH4 2XU, United Kingdom
Local Institution - 0047

Miami, Florida, 33136, United States
Local Institution - 0050

Oxford, Oxfordshire, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.